UK markets close in 3 hours 43 minutes
  • FTSE 100

    7,150.21
    +124.74 (+1.78%)
     
  • FTSE 250

    18,565.82
    +250.51 (+1.37%)
     
  • AIM

    871.95
    +4.49 (+0.52%)
     
  • GBP/EUR

    1.1671
    +0.0033 (+0.29%)
     
  • GBP/USD

    1.1894
    -0.0058 (-0.49%)
     
  • BTC-GBP

    16,912.48
    +258.19 (+1.55%)
     
  • CMC Crypto 200

    435.74
    -4.29 (-0.97%)
     
  • S&P 500

    3,831.39
    +6.06 (+0.16%)
     
  • DOW

    30,967.82
    -129.44 (-0.42%)
     
  • CRUDE OIL

    100.08
    +0.58 (+0.58%)
     
  • GOLD FUTURES

    1,759.70
    -4.20 (-0.24%)
     
  • NIKKEI 225

    26,107.65
    -315.82 (-1.20%)
     
  • HANG SENG

    21,586.66
    -266.41 (-1.22%)
     
  • DAX

    12,566.07
    +164.87 (+1.33%)
     
  • CAC 40

    5,885.11
    +90.15 (+1.56%)
     

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

·3-min read

DGAP-News: Quidel Corporation
QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS
09.06.2022 / 15:00
The issuer is solely responsible for the content of this announcement.

With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year.

Quidel is the nation’s leading developer of the only rapid point-of-care diagnostic Lyme disease test. In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series.

“The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field while expanding education and awareness programs for the public and physicians. We’re honored to have this collaborative partnership.”

As part of its collaboration, Quidel will serve as sponsor for GLA’s Lyme awareness month as well as a series of educational PACE-accredited webinars. These events provide new information on various Lyme topics in an open discussion format, all designed to bring awareness around the Lyme disease epidemic, with rapid ways to diagnose and treat it. In addition, Quidel will be a sponsor for the GLA Global Gala 2022, the organization’s premier fundraising event to be held in October.

About Quidel Corporation

Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’ s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’ s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities, and the world. For more information about Quidel, visit quidel.com.

Contact Details

Jim Yeager

+1 818-264-6812

jim@breakwhitelight.com

Company Website

http://Quidel.com


News Source: News Direct


09.06.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Quidel Corporation

United States

EQS News ID:

1372291


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting